

Contrasting Patterns of Serologic and Functional Antibody Dynamics to *Plasmodium falciparum* Antigens in a Kenyan Birth Cohort

Arlene E. Dent,^{a,b} Indu Malhotra,^a Xuelie Wang,^c Denise Babineau,^{c,*} Kee Thai Yeo,^b Timothy Anderson,^{d,*} Rhonda J. Kimmel,^a Evelina Angov,^e David E. Lanar,^e David Narum,^f Sheetij Dutta,^e Jack Richards,^g James G. Beeson,^{g,h} Brendan S. Crabb,^g Alan F. Cowman,ⁱ Toshihiro Horii,^j Eric Muchiri,^k Peter L. Mungai,^{a,k} Christopher L. King,^a James W. Kazura^a

Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA^a; Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA^b; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA^c; School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA^d; Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA^e; Laboratory of Malaria Immunology and Vaccinology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA^f; Burnet Institute, Melbourne, Australia^g; Department of Microbiology, Monash University, Melbourne, Australia^h; Walter and Eliza Hall Institute of Medical Research, Parkville, Australiaⁱ; Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan^j; Division of Vector Borne and Neglected Tropical Diseases, Ministry of Public Health and Sanitation, Nairobi, Kenya^k

IgG antibodies to *Plasmodium falciparum* are transferred from the maternal to fetal circulation during pregnancy, wane after birth, and are subsequently acquired in response to natural infection. We examined the dynamics of malaria antibody responses of 84 Kenyan infants from birth to 36 months of age by (i) serology, (ii) variant surface antigen (VSA) assay, (iii) growth inhibitory activity (GIA), and (iv) invasion inhibition assays (IIA) specific for merozoite surface protein 1 (MSP1) and sialic acid-dependent invasion pathway. Maternal antibodies in each of these four categories were detected in cord blood and decreased to their lowest level by approximately 6 months of age. Serologic antibodies to 3 preerythrocytic and 10 blood-stage antigens subsequently increased, reaching peak prevalence by 36 months. In contrast, antibodies measured by VSA, GIA, and IIA remained low even up to 36 months. Infants sensitized to *P. falciparum* *in utero*, defined by cord blood lymphocyte recall responses to malaria antigens, acquired antimalarial antibodies at the same rate as those who were not sensitized *in utero*, indicating that fetal exposure to malaria antigens did not affect subsequent infant antimalarial responses. Infants with detectable serologic antibodies at 12 months of age had an increased risk of *P. falciparum* infection during the subsequent 24 months. We conclude that serologic measures of antimalarial antibodies in children 36 months of age or younger represent biomarkers of malaria exposure rather than protection and that functional antibodies develop after 36 months of age in this population.

Naturally acquired immunity to malaria develops slowly over time in children in areas of malaria endemicity as a consequence of repeated infections (1). Antibodies play a key role in this immunity, as demonstrated by passive antibody transfer from immune adults to children with clinical malaria, resulting in reduction of symptoms and parasitemia (2, 3). Very young infants <6 months old are relatively protected from clinical malaria, a phenomenon thought to be mediated primarily by maternal IgG antibodies transferred to the fetus in the last trimester of pregnancy. High levels of fetal hemoglobin and nutritional factors may also contribute to decreased malaria susceptibility during early infancy (4–6). Maternal IgG antibodies detectable in cord blood progressively decrease, leaving infants older than approximately 4 to 6 months of age vulnerable to *Plasmodium falciparum* infection and symptomatic malaria. With repeated infections and increasing age, young infants subsequently acquire IgG antibodies directed against many *P. falciparum* antigens. The exact antigenic targets of these antibodies, their relative rates of development, and how they function to mediate protection from infection and symptomatic malaria are incompletely understood.

Antimalarial IgG antibodies may potentially mediate protection through multiple functions, e.g., blocking sporozoite invasion of hepatocytes and merozoite invasion of erythrocytes, opsonizing merozoites and infected erythrocytes expressing variant surface antigens on their surface for phagocytosis, and fixation and activation of complement on the merozoite surface with resultant parasite lysis. An increasing number of *P. falciparum* anti-

gens have been identified as relevant to naturally acquired immunity and, thus, are considered potential vaccine targets (7–9). Evaluation of infant antibody responses to *P. falciparum* has relied mainly on serologic assays, with some studies indicating that such antibodies are associated with protection from infection and symptomatic malaria (10, 11), while others conclude that they are biomarkers of exposure which, when elevated, are associated prospectively with an increased risk of malaria (6, 12–14). Measure-

Received 5 August 2015 Returned for modification 23 September 2015

Accepted 20 November 2015

Accepted manuscript posted online 9 December 2015

Citation Dent AE, Malhotra I, Wang X, Babineau D, Yeo KT, Anderson T, Kimmel RJ, Angov E, Lanar DE, Narum D, Dutta S, Richards J, Beeson JG, Crabb BS, Cowman AF, Horii T, Muchiri E, Mungai PL, King CL, Kazura JW. 2016. Contrasting patterns of serologic and functional antibody dynamics to *Plasmodium falciparum* antigens in a Kenyan birth cohort. *Clin Vaccine Immunol* 23:104–116. doi:10.1128/CVI.00452-15.

Editor: P. P. Wilkins

Address correspondence to Arlene E. Dent, arlene.dent@case.edu.

* Present address: Denise Babineau, Rho Federal Systems Division, Chapel Hill, North Carolina, USA; Timothy Anderson, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/CVI.00452-15>.

Copyright © 2016 Dent et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

ments of alternative functional antibody activities, such as the variant surface antigen (VSA) assay, growth inhibitory activity (GIA), and invasion inhibitory assays (IIA), that reflect impaired interaction of merozoite ligands with the erythrocyte surface membrane have been developed (15–20). There have been few studies of VSA antibodies focused on infants in areas of malaria endemicity (21). Antibodies that inhibit the growth of *P. falciparum* *in vitro* have been used to assess vaccine efficacy in animal models and malaria-naïve human volunteers (22–26). *P. falciparum* GIA has been associated with protection from infection in children in some studies, but this has not been a consistent finding (15, 27, 28).

The objectives of our study were to advance the knowledge on the breadth and dynamics of various infant antimalarial antibody responses and to determine whether specific antigens and functional antibody responses may be prioritized during the development of naturally acquired immunity in early childhood. Infants born in Msambweni, Kenya, from 2006 to 2009 were followed every 6 months from birth to 36 months. Plasma samples from the study participants were examined for the presence and magnitude of serologically determined IgG antibodies directed against multiple preerythrocytic and blood stage antigens over time. In addition, we measured IgG antibodies to VSA expressed by three different *P. falciparum* laboratory-adapted isolates: 3D7, a widely used reference isolate; BFD06, isolated from an adult traveler returning from Burkina Faso presenting to the hospital with severe malaria (29); and Msam06, isolated from a child presenting with acute uncomplicated malaria at Msambweni District Hospital, Kenya (30). We evaluated GIA with D10 and W2mef parasites and the acquisition of invasion-inhibitory antibodies directed against MSP1-19 (16, 31) and sialic acid-dependent invasion pathways (32).

MATERIALS AND METHODS

Study population and ethical approval. Healthy, pregnant mothers were recruited from antenatal clinics at Msambweni District Hospital, Coast Province, Kenya, from 2006 to 2009, as previously described (33). Malaria endemicity at the time was in transition from moderate transmission in 2007 to low transmission in 2009 (34). Per the Kenya Ministry of Health national policy, women received intermittent preventive treatment for malaria with sulfadoxine-pyrimethamine beginning in the second trimester in addition to iron, folic acid, and bed nets as part of routine care. Full-term healthy neonates were enrolled in the study. Cord blood was collected after delivery, and blood was collected from the infants (by venipuncture) every 6 months until 36 months of age. All infants with data for this study were born to HIV-negative mothers, and all women provided written, informed consent. The study was approved by the institutional review boards at the Kenya Medical Research Institute and Universities Case Medical Center.

Samples and sample preparation. Cord blood was collected in heparinized bags from placentas of full-term deliveries (35). Plasma was stored at -20°C . Cord blood mononuclear cells (CBMCs) were isolated using Ficoll-Paque Plus (GE Healthcare, NJ) density gradient centrifugation and cryopreserved in 90% fetal bovine serum plus 10% dimethyl sulfoxide (Sigma-Aldrich, MO) (35). Heparinized blood from infants was centrifuged, and plasma was stored at -20°C .

***In utero* sensitization to malaria antigens.** Freshly isolated CBMCs were used to evaluate cytokine production in response to known T-cell epitopes within the C-terminal 83-kDa fragment of merozoite surface protein 1 (MSP1), the 42-kDa fragment of recombinant MSP1 (MSP1₄₂ FVO and MSP1₄₂ 3D7), and PfP0 (a *P. falciparum* ribosomal phosphoprotein [36]), as previously described (35). A newborn was considered

sensitized to malaria antigens *in utero* when one of the following three conditions were met: (i) by gamma interferon (IFN- γ) enzyme-linked immunosorbent spot assay (ELISPOT), there were >4 cytokine-secreting cells/ 10^6 CBMCs in response to MSP1 peptides/MSP1₄₂/PfP0 and no secreting cells were detected in negative-control wells containing media alone; (ii) by IFN- γ ELISPOT, in cases where cytokine-secreting cells were observed in negative-control wells, the number of spots generated by MSP1-driven CBMCs was 2-fold greater than control wells; (iii) by enzyme-linked immunosorbent assay (ELISA) for IFN- γ , interleukin 2 (IL-2), IL-5, or IL-13, net cytokine production by CBMCs in response to MSP1 peptides/MSP1₄₂/PfP0 was at least 2-fold greater than that of negative-control wells (35). If these criteria were not met, the newborn was categorized as not sensitized.

Diagnosis of infection by blood smear and PCR. All blood samples were examined for *P. falciparum* parasites. Thick and thin blood smears were prepared, stained with 5% Giemsa, and examined by light microscopy for *P. falciparum*-infected erythrocytes. A slide was deemed negative when no parasites were seen after counting microscopic fields containing at least 200 leukocytes. After Ficoll processing of cord blood and infant blood samples, DNA from 200 μl of the erythrocyte pellet was extracted using the QIAamp 96 DNA blood kit (Qiagen, Valencia, CA). The DNA was subjected to a *P. falciparum*-specific PCR/ligase detection reaction-fluorescence microsphere assay, as previously described (37). *P. falciparum* infections ($n = 39$) were detected in asymptomatic pregnant women during this time, and extracted DNA was utilized for MSP1-19 haplotype determination (see below).

Serologic IgG and IgM antibodies to *P. falciparum* antigens measured by Luminex multiplex assay. Recombinant antigens tested included the following proteins: liver stage antigen 1 (LSA1) (38); circumsporozoite protein (CSP) (39); cell-traversal protein for ookinetes and sporozoites (PfCelTOS) (40); serine repeat antigen 5 (SERA5; SE50 [41], SE36 [42]); MSP1 42-kDa fragment (MSP1₄₂ 3D7 [43], FVO [44], and FUP [45]); erythrocyte binding antigen 140 (EBA140) (46), EBA175 (47), and EBA181 (48); and apical membrane antigen 1 (AMA1 3D7) (49) and FVO (50). The proteins AMA1, PfCelTOS, and CSP and the MSP1 alleles were all good manufacturing practice (GMP)-quality proteins and therefore had no host cell contamination. We did not find that there was high reactivity of the responses to the other antigens compared with these GMP-quality proteins. These antigens were selected, as previous cohort studies have indicated that antibodies against them have been generally associated with protective immunity, are targets of acquired invasion-inhibitory antibodies, and are vaccine candidates (17, 51–54). Carboxylated microspheres (Luminex, Austin, TX) were coupled to the proteins using the manufacturer's protocol and as described previously (55–57). Antigen-specific IgG was detected by incubating 1,000 beads of each antigen per well with a 1:1,000 plasma dilution in a final volume of 100 μl . Antigen-specific IgM was detected using the same incubation techniques and a 1:100 plasma dilution. Plasma samples from 4 North American malaria-naïve adults were used as negative controls for each plate. A pool of Kenyan adult plasma was used as a positive control on all plates to ensure assay performance and minimal plate-to-plate variation. For IgG antibody responses, the mean fluorescence intensity (MFI) of individual Kenyan plasma samples was normalized to the mean MFI of the negative controls to obviate plate to plate variations. A positive value was assigned if the normalized value was >1.5 -fold over malaria-naïve controls. For IgM, a positive value was designated if the normalized value was >5 -fold over negative controls. All positive values were also greater than the mean plus 3 standard deviations (SD) of the value of the individual negative-control plasma samples.

Growth inhibition assays. D10 (D10-PfM3' [16]) and W2mef parasites were utilized in GIAs, as previously described (15). Briefly, ring-stage parasites were synchronized twice by sorbitol lysis (5% D-sorbitol; Sigma, St. Louis, MO) and allowed to mature to late trophozoite/schizont stages. Parasites were cultured at 4% hematocrit in RPMI 1640 supplemented with 25 mg/ml of HEPES, 2 mg/ml of sodium bicarbonate, 0.5% of Albu-

max II (Gibco, Grand Island, NY), 2.4 mM L-glutamine, 0.08 mg/ml of gentamicin, and 0.2 mM hypoxanthine. Cultures were maintained at 37°C in an atmosphere of 5% CO₂, 1% O₂, and 94% N₂. Purified parasites were adjusted to 0.5% infected erythrocytes with a final 2% hematocrit, a 1:10 plasma dilution (not heat inactivated at 56°C and, thus, containing complement proteins required for activation by classical and alternate pathways, although freezer storage could make complement function suboptimal), and a 100- μ l final volume in 96-well flat-bottom microtiter plates. The cultures were incubated for 26 h to allow for schizont rupture and merozoite invasion (monitored by microscopy to ensure full schizont rupture). Twenty-five microliters of resuspended cultures was removed, fixed with 0.25% glutaraldehyde in phosphate-buffered saline (PBS) for 45 min, and placed in 10 \times SYBR green I (Molecular Probes, Eugene, OR)—400 μ l of 1 \times PBS for >24 h at 4°C to stain parasite DNA. Stained cells were examined with a BD LSR II flow cytometer to collect data from a minimum of 5 \times 10⁴ cells. A Becton-Dickinson fluorescence-activated cell sorter (FACS) equipped with Diva 5.01 software was used to collect and FlowJo 8.5.1 was used to analyze cytometry data. The mean parasitemia for duplicate wells was used to determine the percent GIA calculated with the following equation: 100 – (test plasma parasitemia/non-immune plasma parasitemia \times 100). Plasma samples from 4 North Americans who had never been exposed to malaria were pooled as the nonimmune plasma controls.

Target-specific invasion inhibition assays. Methods to quantify MSP1-19 IIA and sialic acid-dependent invasion IIA (Sial Dep IIA) were as described previously (16, 32, 58). Briefly, for the MSP1-19-specific IAs, D10-PfM3' and an isogenic D10-PcMEGF parasite line in which the *Plasmodium chabaudi* orthologue replaces the *P. falciparum* MSP1-19 region were tested in parallel. Greater inhibition of D10-PfM3' than D10-PcMEGF parasites was interpreted as inhibitory antibodies targeting Pf-MSP1-19. For Sial Dep IIA, the W2mef isolate and the W2mef with genetic deletion of EBA175 (Δ EBA175) isolate were tested in parallel. W2mef invades predominantly via sialic acid-dependent invasion pathways, and W2mef Δ EBA175 invades via sialic acid-independent pathways. Greater inhibition of W2mef parental versus W2mef Δ EBA175 was interpreted as inhibitory antibodies to sialic acid-dependent invasion (32). For both assays, ring-stage parasites were synchronized twice by sorbitol lysis and allowed to mature to late trophozoite/schizont stages. Parasites were adjusted to 4% hematocrit with 0.5% *P. falciparum*-infected erythrocytes, and 50- μ l aliquots were placed in 96-well, flat-bottom microtiter plates with an equal volume of 1:5 prediluted plasma in culture medium (final plasma dilution, 1:10; final volume, 100 μ l). The same batch of prediluted plasma was added to the two parasite lines in the same assays. The cultures were incubated for 26 h to allow for schizont rupture and merozoite invasion. Then, 25 μ l of resuspended cultures was removed, fixed with 0.25% glutaraldehyde—PBS for 45 min, and placed in 10 \times SYBR green I (Molecular Probes, Eugene, OR)—400 μ l of 1 \times PBS for >24 h at 4°C (15, 58). Stained cells were examined with a BD LSR II flow cytometer to collect data from a minimum of 5 \times 10⁴ cells using the Becton-Dickinson FACS Diva 5.01. Ring-stage parasitemia was calculated by quantifying singly infected erythrocytes plus multiply infected erythrocytes (quantified as having two intracellular rings) divided by the total erythrocytes according to flow cytometry gating previously described (15, 58). FlowJo 8.5.1 was used to analyze cytometry data. The mean number of ring-stage parasitemia for duplicate wells was calculated, and results were expressed as a percentage of the ring-stage parasitemia of nonimmune control plasma (derived from 4 North Americans who had never been exposed to malaria) in parallel cultures. The percentage change of invasion inhibition antibodies specifically attributable to MSP1-19 antibodies (MSP1-19 IIA) or Sial Dep IIA was calculated by subtracting the percentage of invasion of the parent *P. falciparum* strain (D10-PfM3' or W2mef) relative to non-immune controls from the percent invasion of the mutated *P. falciparum* strain (D10-PcMEGF or W2mef Δ EBA175) relative to nonimmune controls. A positive response was defined as \geq 5% inhibition attributable to MSP1-19 IIA or Sial Dep IIA.

Antibodies to variant surface antigens. Anti-VSA IgG antibodies were measured by flow cytometry as previously described, with minor modifications (59, 60); these antibodies appear to predominantly target the infected erythrocyte surface antigen *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) (19). Three *P. falciparum* isolates were used: (i) 3D7, a widely used reference isolate, and antibodies to this isolate were previously associated with protection to malaria in Kenyan children (19, 61); (ii) BFD06, which was isolated from an adult traveler with acute severe malaria returning from Burkina Faso in 2006 (29); and (iii) Msam 06, which was isolated in 2006 from a child with acute uncomplicated malaria in Msambweni, Kenya, the study site for this cohort (30). *P. falciparum* isolates from the two acute malaria patients were adapted to *in vitro* culture. Parasites were grown in group O erythrocytes, synchronized, harvested at the late trophozoite stage, and cryopreserved. All plasma samples were processed at the same time for each individual parasite line. Positive-control plasma consisted of pooled plasma samples from 8 malaria-immune Kenyan adults, and negative-control plasma consisted of pooled plasma samples from 4 malaria-naive North Americans. Thawed parasites were adjusted to 0.2% hematocrit. Two microliters of heat-inactivated test plasma was added to each well of a U-bottom 96-well microtiter plate. Then, 38 μ l of the adjusted thawed parasites was added to each well (final plasma dilution, 1:20) and incubated for 60 min at room temperature. Between incubation steps, cells were washed three times with PBS and 0.1% casein. Forty microliters of 1:100 diluted polyclonal rabbit anti-human IgG (Dako, Carpinteria, CA) was added and incubated for 30 min at room temperature, followed by 40 μ l of 1:100 diluted Alexa-Fluor-647-conjugated donkey anti-rabbit IgG (Molecular Probes, Eugene, OR) with 10 \times SYBR green I incubated for 30 min at room temperature. Cells were resuspended in 200 μ l PBS—0.1% casein and were examined with a BD LSR II flow cytometer. Infected erythrocytes were differentiated from noninfected erythrocytes by SYBR green fluorescence. For quantification of the Alexa-Fluor, the geometric mean fluorescent intensity (GeoMFI) of each population was used. The magnitude of VSA reactivity was calculated as the GeoMFI of infected erythrocytes minus the GeoMFI of non-infected erythrocytes. A positive response was defined as GeoMFI greater than the mean plus 3 SD of the North American negative controls.

MSP1-19 haplotype detection. DNA was extracted from 200 μ l of venous blood using the QIAamp DNA blood minikit (Qiagen Corp., Valencia, CA). PCR amplification using MSP1-19-specific and *P. falciparum* small subunit rRNA-specific primers, the ligase detection reaction—fluorescent microsphere assay (LDR-FMA), and haplotype assignment based on allele-specific mean fluorescence intensity were performed as previously described (55, 62). Importantly, if four alleles (Q, E, KNG, and TSR) were detected in a single sample, we conservatively assumed that only two haplotypes were present. Therefore, the maximum number of haplotypes assigned to any infection was two.

Statistical analysis. We estimated the probability of positive antibody responses over time using restricted cubic splines, and we used generalized linear mixed models to estimate the probability of anti-malaria antibody responses over time among newborns sensitized and not sensitized to MSP1 *in utero*. A generalized estimation equation regression model was used to estimate the rate of change in the probability of presence of each antibody response over time and to assess if the mean rate of change in the probability of detecting serological antibodies after 12 months of age was different than the mean rate of change in the probability of detecting VSA, GIA, and IIA antibodies after 12 months of age. Cox proportional hazards regression models were fitted to investigate the association between antibody responses at birth or at 12 months of age and the incidence of *P. falciparum* infection during the follow-up time period.

RESULTS

IgG antibody magnitude and prevalence in cord blood. We report the malarial antibody dynamics of 84 infants who had approximately 4.3 blood samples per participant with a mean follow-up time of 29 months (minimum, 4 months; maximum, 39

TABLE 1 Magnitude and prevalence of IgG antibodies in cord blood

Assay/antigen tested (<i>P. falciparum</i> isolate)	Sample size (no.)	Mean (SD)/median (IQR) ^a	No. (%) positive
Serology (fold increase in MFI over negative controls)			
LSA1	78	24.7 (42.6)/4.7 (1.6–27.8)	59 (75.6)
CSP	78	29.5 (39.7)/11.4 (3.3–40.0)	68 (87.2)
PfCelTOS	78	0.6 (1.4)/0.0 (0.0–0.0)	15 (19.2)
SE50	78	0.6 (2.1)/0.0 (0.0–0.0)	11 (14.1)
SE36	78	3.1 (6.9)/0.0 (0.0–2.6)	34 (43.6)
MSP1 ₄₂ (3D7)	78	9.3 (11.9)/5.8 (0.0–12.0)	58 (74.4)
MSP1 ₄₂ (FVO)	78	6.5 (9.5)/2.3 (0.0–10.6)	46 (59.0)
MSP1 ₄₂ (FUP)	78	12.2 (13.8)/6.8 (2.4–16.6)	68 (87.2)
EBA140	78	8.7 (19.6)/1.7 (0.0–7.3)	41 (52.6)
EBA175	78	9.9 (14.7)/3.7 (0.0–14.5)	49 (62.8)
EBA181	78	9.6 (17.9)/2.7 (0.0–8.6)	51 (65.4)
AMA1 (3D7)	78	81.0 (46.4)/88.1 (48.4–101.6)	76 (97.4)
AMA1 (FVO)	78	96.7 (61.2)/113.9 (39.5–131.2)	76 (97.4)
Variant surface antigen assay (geometric mean MFI)			
BFD 2006	79	40.2 (56.4)/17.0 (11.0–46.0)	42 (53.8)
Msambweni 2006	79	37.4 (40.9)/21.0 (13.0–44.0)	54 (69.2)
3D7	79	24.2 (28.0)/13.5 (8.0–30.0)	37 (47.4)
Growth and invasion inhibition assay (percent inhibition)			
Sial Dep IIA	84	2.8 (7.5)/0.0 (0.0–0.0)	12 (14.6)
W2mef GIA	84	11.3 (15.6)/6.0 (0.0–19.6)	31 (37.8)
MSP1-19 IIA	84	0.8 (2.7)/0.0 (0.0–0.0)	5 (6.1)
D10 GIA	84	4.2 (8.5)/0.0 (0.0–4.6)	18 (22.0)

^a IQR, interquartile range.

months; median, 33 months). The presence and magnitude of cord blood maternal IgG antibodies are shown in [Table 1](#). Serologic antibodies were common, with anti-AMA1 (3D7 and FVO) having the highest prevalence (97.4%) and magnitude, and antibodies to PfCelTOS and SERA5 (SE50) having the lowest prevalence (14.1% to 19.2%) and magnitude. VSA reactive antibodies were moderately prevalent in cord blood (47.4% to 69.2%). GIAs and Sial Dep IIA were very low in cord blood, with virtually no MSP1-19 IIA detected (6.1%).

Antigens utilized in serologically measured antibodies were selected to reflect the circulating allele frequencies in the population. For example, MSP1 is the most abundant protein found on the merozoite surface and a vaccine candidate. As the merozoite invades the erythrocyte, MSP1 is processed into several fragments, among which the C-terminal 19-kDa fragment remains on the merozoite surface during invasion (63–65). MSP1-19 is composed of 98 highly conserved amino acids, with the exception of residues 1644 (E/Q), 1691 (T/K), 1700 (S/N), and 1701 (R/G). Nonsynonymous changes at these positions result in four predominant haplotypes: ETSR (3D7/PNG-MAD20), EKNG (FUP/Uganda-PA), QKNG (FVO/Wellcome), and QTSR (Indo) (66–69). We found that the frequencies of circulating MSP1-19 haplotypes in this region were 44% EKNG (FUP), 39% QKNG (FVO), 8% ETSR (3D7), and 0% QTSR. Therefore, the MSP1-19 FUP, FVO, and 3D7 alleles of the recombinant proteins used should reflect the circulating alleles at the time. Additionally, antibodies to MSP1-19 haplotypes are thought to be broadly cross-reactive (55). The frequency of AMA1 alleles was not measured for this cohort. How-

ever, a study conducted in 2000 measured *P. falciparum* AMA1 haplotype frequencies in nearby Kilifi and found that there were 78 unique haplotypes in the area but that antibodies to AMA1 3D7, AMA1 FVO, and AMA1 HB3 were highly correlated (70). Thus, using the AMA1 3D7 and FVO alleles in the assays should reflect the circulating alleles at the time of this study.

IgG antibody prevalence in the longitudinal infant cohort plasma. Examples of raw data results for the various antibody assays over time are shown in Fig. S1 in the supplemental material. To visualize the complex patterns of antibody responses more clearly, we plotted the probability of the presence of each response over time using restricted cubic splines. [Figure 1](#) illustrates the probability of detecting serologically measured antibody responses over time. In general, maternal antibodies against each recombinant antigen measured in cord blood waned to a nadir by 6 to 9 months of age. The probability of having IgG antibodies to each antigen then increased over time and generally returned to the prevalence observed in cord blood by 36 months of age. Antibodies to AMA1 (3D7 and FVO) were of the highest magnitude in cord blood and did not wane as rapidly as other antibodies. Antibodies to PfCelTOS and SERA5 were essentially absent from cord blood, with infants and young children gradually acquiring IgG antibodies to these antigens over 36 months.

VSA antibodies waned by 6 to 9 months of age and were not (re)acquired during infancy and early childhood ([Fig. 2A](#)). W2mef GIA, though not highly prevalent in cord blood, waned by 6 months of age and subsequently (re)appeared at a low rate, while D10 GIA had a consistently negligible prevalence ([Fig. 2B](#)). Sial




FIG 1 Serological responses in infants over time. (A) Detection probability (y axis) of each antibody in infants over time (x axis). Responses to specific antigens are indicated in each plot box. (B) Magnitude of antibodies in cord blood for each indicated antigen expressed as fold increase relative to negative-control North Americans (NAM) (mean + standard error of the mean).

Dep IIA prevalence was overall higher than MSP1-19 IIA, but both were low throughout infancy (Fig. 2C).

We used a generalized estimation equation regression model to estimate the rate of change in the probability of the presence of each antibody response over time using cord blood antibody levels as the baseline or comparator group. Due to the presence of non-linear relationships in the curves, segmented linear spline terms were used to provide separate estimates of the odds ratios per 1 month change in age within the first 6 months after birth and after 6 months of age. The exception for this analysis was for serologically measured AMA1 antibodies, where we used 12 months of age as the cutoff. The magnitude of cord blood antibodies against AMA1 was high, and infant catabolism of these reached a nadir at 12 months; thus, we compared the rate of waning to the rate of acquisition based on this time point. Additionally, we tested whether there was a significant difference between rates of change of antibody responses before and after 6 months of age. Table 2 presents this analysis for each antibody response as it relates to age ≤ 6 months and > 6 months. As an example, during the first 6 months after birth, there was an associated 25% odds reduction each month in the presence of EBA181 antibodies (odds ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.82; $P < 0.001$), while, after 6 months of age, there was an associated 6% higher odds each month for the presence of EBA181 antibodies (odds ratio, 1.06; 95% CI, 1.03 to 1.08; $P < 0.001$). Similar results were observed for the other serologically measured antibody responses. With regard

to VSA, taking the VSA BFD 2006 reactive IgG as an example, during the first 6 months after birth, each month of age was associated with 24% reduced odds of detecting this antibody (odds ratio, 0.76; 95% CI, 0.69 to 0.84; $P < 0.001$), and, after 6 months of age, this odds value did not significantly increase (odds ratio, 1.01; 95% CI, 0.99 to 1.03; $P = 0.33$). Similar results were observed for the other *P. falciparum* isolates. In general, serologically measured responses waned by 6 to 12 months of age and subsequently increased to reach their highest prevalence by 36 months. In contrast, VSA, GIA, and IIA antibodies waned by 6 to 9 months of age and were not acquired to any great extent during infancy and early childhood. Fig. S2 in the supplemental material illustrates the difference in acquisition/dynamics of serologically measured antibodies versus VSA, GIA, and IIA antibodies. Based on the antibody dynamics observed, a generalized estimation equation regression model was used to assess if the mean rate of change in the probability of having serologic anti-malaria antibodies after 12 months was different than the mean rate of change in the probability of detecting VSA, GIA, and IIA antibodies. Averaging over 13 serological antibody responses, the probability of detecting antibodies increased significantly after 12 months of age. Each month of age was associated with 5% higher odds of detecting the antibodies (odds ratio, 1.05; 95% CI, 1.02 to 1.08; $P = 0.002$). Averaging over the 7 VSA, GIA, and IIA antibody responses, the probability of detecting antibodies did not change significantly over time after 12 months (odds ratio, 0.99; 95% CI, 0.98 to 1.00;




FIG 2 Infant VSA, GIA, and IIA antibody responses over time. (A) Detection probability (*y* axis) of each VSA measured antibody response in infants over time (*x* axis). VSA responses to each *P. falciparum* isolate are indicated. Bar graph to the right of the plot shows the geometric mean fluorescence intensity (GeoMFI) for VSA antibodies in cord blood (mean + standard error of the mean [SEM]). (B) Detection probability (*y* axis) of W2mf and D10 GIA antibody responses in infants over time (*x* axis). Bar graph to the right of the plot shows the percentage of growth inhibition of GIA responses in cord blood (mean + SEM). (C) Detection probability (*y* axis) of Sial Dep and MSP1-19 IIA antibody responses in infants over time (*x* axis). Bar graph to the right of the plot shows the percentage of invasion inhibition responses in cord blood (mean + SEM).

$P = 0.16$). The mean rate of change in the probability of detecting 13 serological antimalarial antibody responses after 12 months was significantly different than the mean rate of change in the probability of detecting 7 VSA, GIA, and IIA antibodies after 12 months ($P < 0.001$). Thus, infants acquired serologically measured antibodies but not VSA, GIA, and IIA antibodies after 12 months of age.

While the prevalence of serologic antibody responses at 36 months of age was similar to cord blood prevalence, the magnitude of antibody responses was considerably lower. Cord blood levels of antibodies against MSP1₄₂ (3D7, FVO, FUP), AMA1 (3D7, FVO), LSA1, EBA175, SE50, and CSP were significantly higher than in 36-month-old young children (Fig. 3A and B). The levels of the 3 VSA antibodies were also significantly higher in cord blood than in 36-month-old young children (Fig. 3C). The GIA and IIA antibodies, however, were low in both groups (Fig. 3D). The only exception to this trend was serologically measured antibodies against PfCelTOS that, in cord blood, had a median of 1, whereas the 36-month-old young children had a median of 3.1-fold increase relative to malaria-naive North American negative controls ($P <$

0.0001, Mann Whitney test; Fig. 3B). It is unknown whether this increase has biological relevance, although it is noted that the magnitude of response is considerably lower than other antigens.

Fetal sensitization to malaria and acquisition of IgG antibodies. We hypothesized that newborns that were sensitized to malaria antigens *in utero* would have antibody responses to multiple antigen targets of broader diversity (serologic and functional) at earlier time points during infancy compared to newborns that were not sensitized. In this cohort, 76 infants had complete sensitization and antibody data. Thirty neonates were classified as sensitized, and 46 neonates were classified as not sensitized, based on CBMC recall responses to malaria antigens, as measured by IFN- γ ELISPOT and cytokine production. We found no statistical difference in either the prevalence or magnitude of IgG antibodies in cord blood regardless of sensitized or not sensitized categorization. Examination of longitudinal data revealed no difference in the rate of change (waning or acquisition) for any antimalarial antibodies between sensitized and not sensitized infants/young children over time (Table S1 in the supplemental material). Thus, fetal sensitization

TABLE 2 IgG antibody rates of change before and after 6 months of age

Assay/antigen tested (<i>P. falciparum</i> isolate)	Time period	Odds ratio (95% CI ^a) per 1 mo age change	P	P difference between rates of change ^b
Serology				
LSA1	Before 6 mo ^c	0.72 (0.65–0.80)	<0.001	<0.001
	After 6 mo ^d	1.04 (1.02–1.07)	<0.001	
CSP	Before 6 mo	0.64 (0.57–0.72)	<0.001	<0.001
	After 6 mo	1.04 (1.02–1.06)	<0.001	
PfCelTOS	Before 6 mo	1.16 (1.04–1.28)	<0.001	0.08
	After 6 mo	1.05 (1.03–1.07)	<0.001	
SE50	Before 6 mo	1.20 (1.07–1.34)	0.0025	0.03
	After 6 mo	1.04 (1.02–1.06)	<0.001	
SE36	Before 6 mo	0.88 (0.80–0.98)	0.01	0.003
	After 6 mo	1.04 (1.03–1.06)	<0.001	
MSP1 ₄₂ (3D7)	Before 6 mo	0.75 (0.68–0.82)	<0.001	<0.001
	After 6 mo	1.04 (1.02–1.06)	<0.001	
MSP1 ₄₂ (FVO)	Before 6 mo	0.79 (0.73–0.87)	<0.001	<0.001
	After 6 mo	1.05 (1.03–1.08)	<0.001	
MSP1 ₄₂ (FUP)	Before 6 mo	0.66 (0.58–0.74)	<0.001	<0.001
	After 6 mo	1.05 (1.03–1.08)	<0.001	
EBA140	Before 6 mo	0.85 (0.77–0.92)	<0.001	<0.001
	After 6 mo	1.06 (1.04–1.09)	<0.001	
EBA175	Before 6 mo	0.76 (0.70–0.84)	<0.001	<0.001
	After 6 mo	1.05 (1.03–1.07)	<0.001	
EBA181	Before 6 mo	0.75 (0.68–0.82)	<0.001	<0.001
	After 6 mo	1.06 (1.03–1.08)	<0.001	
AMA1 (3D7)	Before 12 mo	0.76 (0.71–0.81)	<0.001	<0.001
	After 12 mo	1.03 (1.01–1.06)	0.02	
AMA1 (FVO)	Before 12 mo	0.79 (0.75–0.83)	<0.001	<0.001
	After 12 mo	1.04 (1.01–1.07)	0.003	
Variant surface antigen assay				
BFD 2006	Before 6 mo	0.76 (0.69–0.84)	<0.001	<0.001
	After 6 mo	1.01 (0.99–1.03)	0.33	
Msambweni 2006	Before 6 mo	0.60 (0.53–0.68)	<0.001	<0.001
	After 6 mo	1.02 (0.98–1.05)	0.35	
3D7	Before 6 mo	0.63 (0.55–0.73)	<0.001	<0.001
	After 6 mo	1.01 (0.97–1.05)	0.63	
Growth and invasion inhibition assay				
Sial Dep IIA	Before 6 mo	1.18 (1.04–1.34)	0.01	0.02
	After 6 mo	0.98 (0.93–1.04)	0.56	
W2mef GIA	Before 6 mo	0.77 (0.68–0.89)	<0.001	<0.001
	After 6 mo	1.05 (1.00–1.10)	0.07	
MSP1-19 IIA	Before 12 mo	1.03 (0.94–1.13)	0.53	0.31
	After 12 mo	0.93 (0.81–1.08)	0.35	
D10 GIA	Before 12 mo	0.86 (0.78–0.95)	0.004	0.07
	After 12 mo	1.05 (0.92–1.19)	0.491	

^a CI, confidence interval.

^b Difference between rates of change between birth to 6 (or 12) months of age and between 6 months of age and 36 months of age (Fisher's exact test).

^c Compared to cord blood responses.

^d Compared to 6-month responses.

to malaria antigens did not affect subsequent infant acquisition of any antimalarial antibody measured in this cohort.

Infants with serologically measured antimalarial antibody responses were more likely to incur *P. falciparum* infection. We examined the association between cord blood and infant antibodies and the risk of *P. falciparum* infection. The first occurrence of infection was measured by PCR, blood smear, and/or ≥ 6 positive antimalarial IgM responses to the 13 tested antigens. IgM positivity was used as a marker of recent infection. If an infant had IgM antibodies at one time point, invariably they were absent at the

following time point, as has been demonstrated by others (6, 10, 11). Thirty infants had *P. falciparum* infections detected by 36 months of age. Infections were detected in 7 infants younger than 12 months of age. With respect to the prevalence of maternal antimalarial IgG antibodies in cord blood, there was no difference between infants who incurred malaria infections during the entire follow-up period and those who did not. The paucity of malaria infections in infants younger than 12 months prohibited further analyses regarding sensitization status or characterization of antibody responses.




FIG 3 Antibodies in cord blood (open circles) compared to 36-month-old young children (open triangles). Dot plots of serologic antibody responses (fold increase relative to North Americans [NAM]) to specified antigens measured in cord blood and 36-month-old young children (A) and to another set of antigens measured in cord blood and 36-month-old young children (B). Note the smaller y axis in (B) than in (A). (C) GeoMFI of VSA responses measured in cord blood and 36-month-old young children. (D) Percent growth inhibition of GIA and IIA antibody responses measured in cord blood and 36-month-old young children. *, $P = 0.04$; **, $P = 0.0005$; ***, $P = 0.0002$; ****, $P < 0.0001$; horizontal bar when visible represents median values.

To exclude confounding maternal antibody responses, we examined the risk of *P. falciparum* infection after 12 months of age as related to infant antibody responses at the 12-month time point. Sixty-seven infants had 12-month antibody data. Within this subset, malaria infections were detected in 17 infants in the subsequent 24 months of follow-up. Using a Cox proportional hazards regression model, we found that infants with serologically measured antibodies at 12 months were more likely to incur malaria infections than infants who were seronegative (Table 3). Specifically, 12-month-old infants who had IgG antibodies to CSP, SERA5, MSP1₄₂ (FVO), MSP1₄₂ (FUP), EBA140, EBA175, AMA1 (3D7), or AMA1 (FVO) had a statistically significant increased risk of infection (hazard ratio range, 2.64 to 6.21) compared to infants with negative serology at 12 months of age. No increased risk was associated with VSA, GIA, and/or IIA antibody at 12 months, though the prevalence of these antibodies was low.

DISCUSSION

Early infancy is a critical time in the development of immunity to malaria in children born in areas of malaria endemicity. Whereas a relative degree of protection from *P. falciparum* infection and symptomatic malaria is thought to exist from birth to approxi-

mately 6 months of age (4–6, 71–73), subsequent exposure to mosquito-borne transmission during early infancy is accompanied by the absence of *de novo* synthesized fetal hemoglobin and the catabolic loss of maternal IgG antibodies that have passed from the maternal to fetal circulation during the last trimester of pregnancy. More generally, the infant immune system is immature until at least 2 years of age (74). Our prospective study of infants born in an area of malaria endemicity of coastal Kenya from 2006 to 2009 was performed to understand in more detail the interplay between the loss of malaria antigen-specific maternal antibodies present at birth and the subsequent acquisition of infant antibodies that result from natural exposure to *P. falciparum*. In addition to measuring serologic IgG antibodies to *P. falciparum* antigens from birth through early infancy, as several other studies have reported (6, 12, 75), we performed several assays that reflect functional antibody responses that include antibody binding to VSAs expressed on the surface of *P. falciparum*-infected erythrocytes, GIA, and IIA specific for MSP1, and sialic acid-dependent erythrocyte invasion by merozoites. The main conclusions from our study indicate that (i) serologic measures of maternal IgG antibodies to preerythrocytic and blood stage anti-

TABLE 3 Association between presence of IgG antibodies at 12 months of age and first occurrence of a malaria infection after 12 months of age

Assay/antigen tested	No. tested	No. of malaria events	Hazard ratio (95% confidence interval)	P
Serology				
LSA1	67	17	1.84 (0.71–4.77)	0.21
CSP	67	17	2.64 (1.00–6.97)	0.05
PfCelTOS	67	17	2.67 (0.94–7.61)	0.07
SE50	67	17	4.51 (1.46–13.9)	0.009
SE36	67	17	2.35 (0.89–6.19)	0.08
MSP1 ₄₂ (3D7)	67	17	1.90 (0.73–4.99)	0.19
MSP1 ₄₂ (FVO)	67	17	4.37 (1.52–12.6)	0.006
MSP1 ₄₂ (FUP)	67	17	3.13 (1.14–8.57)	0.03
EBA140	67	17	3.27 (1.19–8.95)	0.02
EBA175	67	17	3.12 (1.18–8.25)	0.02
EBA181	67	17	1.76 (0.68–4.56)	0.25
AMA1 (3D7)	67	17	2.98 (1.07–8.33)	0.04
AMA1 (FVO)	67	17	6.21 (1.67–23.1)	0.006
Variant surface antigen assay				
BFD 2006	67	17	2.43 (0.78–7.56)	0.13
Msambweni 2006	67	17	1.00 (0.13–7.60)	1.00
3D7	67	17	2.45 (0.56–10.8)	0.23
Growth and invasion inhibition assay				
Sial Dep IIA	65	17	1.64 (0.60–4.47)	0.34
W2mef GIA	65	17	1.52 (0.49–4.74)	0.47
MSP1-19 IIA	65	17	1.56 (0.36–6.84)	0.55
D10 GIA	65	17	1.49 (0.20–11.3)	0.70

gens wane by 6 months after birth and reappear over the following 24 to 36 months as a consequence of natural malaria exposure; (ii) increased levels of serologic antibodies at 12 months of age are predictive of an increased subsequent risk of *P. falciparum* infection; (iii) VSA and functional antibody responses mediated by maternal antibodies in cord blood disappear within 6 months after birth and, unlike serologically determined antibodies, remain low up to 36 months of age; (iv) *in utero* sensitization to *P. falciparum* is not associated significantly with enhanced antibody responses following the loss of maternal IgG antibodies.

Our observations related to serologic maternal malaria IgG antibodies present at birth (Table 1) indicate that antigenic targets of such antibodies are expressed by both preerythrocytic (CSP, LSA1, PfCelTOS) and blood stage (e.g., MSP1, EBA140, EBA175, EBA181, AMA1, SERA5) parasites. These antibodies increased significantly by 6 months after birth and then gradually increased up to age 36 months. Maternal IgG antibodies detectable in cord blood have previously been reported to be directed against ring-infected erythrocyte surface antigen (RESA), CSP, MSP1-19, MSP3, AMA1, EBA175, and glutamate-rich protein (GLURP) (6, 11–13, 75). Studies of other birth cohorts in sub-Saharan Africa have reported the waning of maternal malarial IgG antibodies by 6 to 9 months of age. Following this loss of maternal antibodies, the level of serologically detectable malaria-specific IgG antibodies gradually increased up to 36 months (Fig. 1). However, these newly acquired antibodies were associated not with protective immunity but with an increased prospective risk of infection, most likely due to increased exposure. Elevated levels of malaria IgG antibodies has previously been found to be a biomarker of increased malaria risk during early infancy in a birth cohort study from Ghana (6). Although we did not compare antibody levels in young infants with those of older children in the Ken-

yan study population described here, a recent study by Stanicic et al. (14) did so in cohorts of 1- to 4- and 5- to 14-year-old Papua New Guinean children. Results of this study in Papua New Guinea indicate that one of the reasons why antibody responses in young infants represent biomarkers of malaria exposure rather than protection from malaria is related to failure of antibody responses to reach a critical protective level, as determined by serology, until age 4 years or older. Mathematical models of antibody half-lives in cohorts of younger and older African children suggest that antibodies in younger children have shorter half-lives than those of older children and that this difference in half-lives may be related to differing populations of long-lived and short-lived antibody-secreting cells in the two age groups (76). Although not measured in this study, IgG subclasses may affect the longevity of circulating antibodies. In general, malaria infection predominantly induces IgG1 and IgG3 isotypes to various *P. falciparum*-specific antigens (14, 52, 77–81). In contrast to serologic measures of antibody responses, our data indicate that functional assays of antibody activity are overall weak at birth, decrease by 6 months, and do not reappear by 36 months of age (Fig. 2). We have previously shown in different infants examined from the same cohort that GIA (D10, 3D7, W2mef, Msam 06) decreased in infants over time until 12 months of age (30). In the present study, only W2mef GIA increased transiently at 18 months of age, but it had low prevalence by 36 months of age. This indicates that, if boosted, the resultant antibodies were short-lived in these 18-month-old young children. It may be that in this infant cohort, antibodies to merozoite antigens did not reach sufficiently high levels to mediate substantial invasion-inhibitory activity. Prior studies have suggested that GIA antibodies are not readily boosted by increasing exposure to malaria (15, 27). However, in young children, GIA antibodies showed some association with malaria exposure transmission level (27). VSA antibodies were

moderately prevalent (47% to 69%) in cord blood, indicating that mothers who were children themselves during a time of higher malaria transmission in coastal Kenya (34) had VSA antibodies transferred to their fetuses in the third trimester. This infant cohort with lower malaria exposure, on the other hand, failed to develop much VSA antibody. Of note, a trend toward higher prevalence of VSA antibodies to BFD06, a parasite taken from a patient with severe malaria, was noted in infants approximately 24 months of age. Others have proposed that children develop VSA antibodies to parasites expressing VSA associated with severe disease earlier in childhood than to those expressing VSA associated with mild or moderate disease (82). These findings are similar to those of Vestergaard et al. (21), who showed that infants residing in a low malaria transmission region of Tanzania had low prevalence and magnitude of VSA antibodies compared to infants residing in regions of high transmission. Nhabomba et al. (11) also found a lack of VSA antibody acquisition in infants up to 2 years of age in Mozambique. Conversely, the parasite isolates used in our study may not have been an accurate representation of the circulating parasites from the region, despite one isolate coming from a child with nonsevere acute malaria from this study cohort. Antibodies to VSA are known to be highly isolate specific among children (83, 84), and may be short lived (85). Therefore, the prevalence of antibodies to any one isolate may be low in young children, as we found here. With respect to antibodies that function to impair merozoite invasion of erythrocytes, we used two assays that assess antibodies to the 19-kDa C-terminal region of MSP1 and antibodies that target sialic acid-dependent invasion pathways (16, 32). MSP1 is involved with the initial low affinity binding of the merozoite to the erythrocyte, with the MSP1-19 portion of the cleaved MSP1 retained as the merozoite invades (86). A secondary interaction is then required with ligands of the EBA family and *P. falciparum* reticulocyte-binding homolog (PfRh) proteins (87). The variable expression of these proteins facilitates the merozoite invading through roughly grouped phenotypes labeled sialic acid-dependent or sialic acid-independent, and variation in their use facilitates evasion of acquired antibodies (32). W2mef generally invades through a sialic acid-dependent pathway. When EBA175 is genetically deleted (W2mef Δ EBA175), it invades through a sialic acid-independent pathway. Thus, plasma that contains antibodies that bind to EBA175, and other ligands of sialic acid-dependent invasion, may inhibit the invasion of W2mef but not W2mef Δ EBA175 parasites. EBA140, EBA181, and PfRh1 may also participate in the sialic acid-dependent pathway (32). With respect to both MSP1-19 and sialic acid-dependent IIA, we found that antibodies with these activities were low to negligible at birth and were not detectable at 36 months. These findings are discordant with serology, as both MSP1₄₂ and EBA175 antibodies were detectable at birth and progressively increased in infants between age 12 and 36 months. This could be explained by antibodies to merozoite antigens being at levels below a threshold concentration to effectively inhibit invasion or by antibodies targeting nonfunctional epitopes. This discordance between serologic and functional measures of antibody responses has been described in other studies (31, 88) and highlights the challenge of validating *in vitro* assays relevant to malaria pathogenesis *in vivo*. Recent studies have identified several such potential functional assays that include evaluating antibodies that opsonize merozoites for phagocytosis or fix complement to inhibit invasion and lyse merozoites (89, 90). Additionally, competitive ELISAs for EBA175 (91) and refined assays examining AMA1 complex responses (92) are in development.

With respect to individual covariates that might impact the acquisition of antibody responses by young infants, we examined the relationship between *in utero* sensitization to malaria and postnatal serologic and functional antibody responses. Studies we conducted in this area of coastal Kenya from 2000 to 2003 have shown that 45% to 60% of newborns were sensitized *in utero* as determined by the cord blood T-cell cytokine responses to malaria antigens (35). This sensitization was associated with rapid acquisition of MSP1-19 IIA relative to newborns that were not sensitized (88). However, in the 2006 to 2009 birth cohort reported here, we found no association of *in utero* T-cell sensitization and accelerated development of antibody responses in young infants. We speculate that this discrepancy is likely related to changes in malaria exposure during the two different time periods. While transmission was stable and relatively high from 2000 to 2003, it decreased significantly from 2007 to 2009 as a result of increasing use of insecticidal bed nets and other public health interventions (34).

In conclusion, results of our study highlight several issues pertinent to the development of naturally acquired immunity during the first 3 years after birth. First, while serologic measures of malaria antigen-specific antibodies are clearly indicative of exposure to *P. falciparum*, they are unlikely to be relevant to protective immunity as opposed to malaria exposure in young infants. In this context, a limitation of our study is that we did not perform active surveillance for symptomatic malaria; thus, our results can only be linked with susceptibility to *P. falciparum* infection. Second, results of various birth cohort studies may vary according to prevailing levels of malaria endemicity during gestation, e.g., maternal malaria exposure and maternal antibodies transferred to the fetus, as well as malaria exposure experienced by infants after the waning of maternal antibodies. Third, our results underscore the need for additional functional antibody assays, e.g., phagocytosis of antibody opsonized merozoites and complement fixation, that have been found to correlate with protection from symptomatic malaria (89, 90). This will be challenging, given the likely complexity and redundancy of host immune and nonimmune mechanisms underlying naturally acquired immunity to malaria.

ACKNOWLEDGMENTS

We thank the study participants in the community in Kenya for their cooperation and the director of the Kenya Medical Research Institute for approval to conduct this study.

This work was supported by NIH grants AI064667 (C.L.K.), AI098511 (A.E.D.), and AI09519 (J.W.K.). A.E.D. was also supported by BWF CAMS 1006818. J.G.B. was supported by the National Health and Medical Research Council of Australia, and the Burnet Institute is supported by the NHMRC IRIIS Scheme and Victorian State Government Operational Infrastructure Support. This research was supported by the Intramural Research Program of the NIAID, NIH.

FUNDING INFORMATION

HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Arlene E. Dent under grant number AI098511. HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Christopher L. King under grant number AI064667. HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to James W. Kazura under grant number AI09519.

REFERENCES

1. Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria. *Clin Microbiol Rev* 22:13–36. <http://dx.doi.org/10.1128/CMR.00025-08>.
2. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and ac-

- quired immunity to human malaria. *Nature* 192:733–737. <http://dx.doi.org/10.1038/192733a0>.
3. McGregor IA. 1964. The passive transfer of human malarial immunity. *Am J Trop Med Hyg* 13(Suppl): 237–239.
 4. Brabin B. 1990. An analysis of malaria parasite rates in infants: 40 years after Macdonald. *Trop Dis Bull* 87:R1–R21.
 5. Macdonald G. 1950. The analysis of malaria parasite rates in infants. *Trop Dis Bull* 47:915–938.
 6. Riley EM, Wagner GE, Ofori MF, Wheeler JG, Akanmori BD, Tetteh K, McGuinness D, Bennett S, Nkrumah FK, Anders RF, Koram KA. 2000. Lack of association between maternal antibody and protection of African infants from malaria infection. *Infect Immun* 68:5856–5863. <http://dx.doi.org/10.1128/IAI.68.10.5856-5863.2000>.
 7. Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, Ogada E, McDade B, Rayner JC, Wright GJ, Marsh K. 2014. New antigens for a multicomponent blood-stage malaria vaccine. *Sci Transl Med* 6:247ra102. <http://dx.doi.org/10.1126/scitranslmed.3008705>.
 8. Dent AE, Nakajima R, Liang L, Baum E, Moormann AM, Sumba PO, Vulule J, Babineau D, Davies DH, Felgner PL, Kazura JW. 2015. *Plasmodium falciparum* protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. *J Infect Dis* 212: 429–438. <http://dx.doi.org/10.1093/infdis/jiv224>.
 9. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG. 2013. Identification and prioritization of merozoite antigens as targets of protective human immunity to *Plasmodium falciparum* malaria for vaccine and biomarker development. *J Immunol* 191:795–809. <http://dx.doi.org/10.4049/jimmunol.1300778>.
 10. Dobaño C, Quelhas D, Quinto L, Puyol L, Serra-Casas E, Mayor A, Nhampossa T, Macete E, Aide P, Mandomando I, Sanz S, Puniya SK, Singh B, Gupta P, Bhattacharya A, Chauhan VS, Aponte JJ, Chitnis CE, Alonso PL, Menendez C. 2012. Age-dependent IgG subclass responses to *Plasmodium falciparum* EBA-175 are differentially associated with incidence of malaria in Mozambican children. *Clin Vaccine Immunol* 19:157–166. <http://dx.doi.org/10.1128/CVI.05523-11>.
 11. Nhabomba AJ, Guinovart C, Jimenez A, Manaca MN, Quinto L, Cistero P, Aguilar R, Barbosa A, Rodriguez MH, Bassat Q, Aponte JJ, Mayor A, Chitnis CE, Alonso PL, Dobano C. 2014. Impact of age of first exposure to *Plasmodium falciparum* on antibody responses to malaria in children: a randomized, controlled trial in Mozambique. *Malar J* 13:121. <http://dx.doi.org/10.1186/1475-2875-13-121>.
 12. Achidi EA, Perlmann H, Salimonu LS, Perlmann P, Walker O, Asuzu MC. 1995. A longitudinal study of seroreactivities to *Plasmodium falciparum* antigens in Nigerian infants during their first year of life. *Acta Trop* 59:173–183. [http://dx.doi.org/10.1016/0001-706X\(95\)00076-Q](http://dx.doi.org/10.1016/0001-706X(95)00076-Q).
 13. Kangoye DT, Nebie I, Yaro JB, Debe S, Traore S, Ouedraogo O, Sanou G, Soulama I, Diarra A, Tiono A, Marsh K, Sirima SB, Bejon P. 2014. *Plasmodium falciparum* malaria in children aged 0–2 years: the role of fetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP). *PLoS One* 9:e107965. <http://dx.doi.org/10.1371/journal.pone.0107965>.
 14. Staniscic DI, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, Richards JS, Robinson LJ, Schofield L, Kazura JW, King CL, Zimmerman P, Felger I, Siba PM, Mueller I, Beeson JG. 2015. Acquisition of antibodies against *Plasmodium falciparum* merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. *Infect Immun* 83:646–660. <http://dx.doi.org/10.1128/IAI.02398-14>.
 15. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW. 2008. Antibody-mediated growth inhibition of *Plasmodium falciparum*: relationship to age and protection from parasitemia in Kenyan children and adults. *PLoS One* 3:e3557. <http://dx.doi.org/10.1371/journal.pone.0003557>.
 16. O'Donnell RA, Saul A, Cowman AF, Crabb BS. 2000. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related *Plasmodium* species. *Nat Med* 6:91–95. <http://dx.doi.org/10.1038/71595>.
 17. Persson KE, Fowkes FJ, McCallum FJ, Gicheru N, Reiling L, Richards JS, Wilson DW, Lopaticki S, Cowman AF, Marsh K, Beeson JG. 2013. Erythrocyte-binding antigens of *Plasmodium falciparum* are targets of human inhibitory antibodies and function to evade naturally acquired immunity. *J Immunol* 191:785–794. <http://dx.doi.org/10.4049/jimmunol.1300444>.
 18. Persson KE, Lee CT, Marsh K, Beeson JG. 2006. Development and optimization of high-throughput methods to measure *Plasmodium falciparum*-specific growth inhibitory antibodies. *J Clin Microbiol* 44:1665–1673. <http://dx.doi.org/10.1128/JCM.44.5.1665-1673.2006>.
 19. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG. 2012. Targets of antibodies against *Plasmodium falciparum*-infected erythrocytes in malaria immunity. *J Clin Invest* 122:3227–3238. <http://dx.doi.org/10.1172/JCI62182>.
 20. Kinyanjui SM, Howard T, Williams TN, Bull PC, Newbold CI, Marsh K. 2004. The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of *Plasmodium falciparum*-infected erythrocytes. *J Immunol Methods* 288:9–18. <http://dx.doi.org/10.1016/j.jim.2004.01.022>.
 21. Vestergaard LS, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, Akanmori BD, Alifrangis M, Bygbjerg IC, Lemnge MM, Staalsøe T, Hviid L, Theander TG. 2008. Differences in human antibody reactivity to *Plasmodium falciparum* variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. *Infect Immun* 76:2706–2714. <http://dx.doi.org/10.1128/IAI.01401-06>.
 22. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW. 2009. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the *Aotus* model. *PLoS One* 4:e8138. <http://dx.doi.org/10.1371/journal.pone.0008138>.
 23. Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG, Jr, Ockenhouse CF, Spring MD. 2013. Results from tandem phase I studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen *Plasmodium falciparum* FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. *Malar J* 12:29. <http://dx.doi.org/10.1186/1475-2875-12-29>.
 24. Remarque EJ, Roestenberg M, Younis S, Walraven V, van der Werff N, Faber BW, Leroy O, Sauerwein R, Kocken CH, Thomas AW. 2012. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults. *PLoS One* 7:e38898. <http://dx.doi.org/10.1371/journal.pone.0038898>.
 25. Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA. 2006. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in *Aotus nancymai* monkeys strongly correlates with anti-MSP1 antibody titer and *in vitro* parasite-inhibitory activity. *Infect Immun* 74:4573–4580. <http://dx.doi.org/10.1128/IAI.01679-05>.
 26. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyiam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG, Jr. 2009. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. *PLoS One* 4:e5254. <http://dx.doi.org/10.1371/journal.pone.0005254>.
 27. McCallum FJ, Persson KE, Mugenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG. 2008. Acquisition of growth-inhibitory antibodies against blood-stage *Plasmodium falciparum*. *PLoS One* 3:e3571. <http://dx.doi.org/10.1371/journal.pone.0003571>.
 28. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S, Doumtabe D, Kone Y, Huang CY, Doumbo OK, Miller LH, Long CA, Pierce SK. 2010. *In vitro* growth-inhibitory activity and malaria risk in a cohort study in Mali. *Infect Immun* 78:737–745. <http://dx.doi.org/10.1128/IAI.00960-09>.
 29. Drew DR, Hodder AN, Wilson DW, Foley M, Mueller I, Siba PM, Dent AE, Cowman AF, Beeson JG. 2012. Defining the antigenic diversity of *Plasmodium falciparum* apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. *PLoS One* 7:e51023. <http://dx.doi.org/10.1371/journal.pone.0051023>.
 30. Wilson PT, Malhotra I, Mungai P, King CL, Dent AE. 2013. Transpla-

- centally transferred functional antibodies against *Plasmodium falciparum* decrease with age. *Acta Trop* 128:149–153. <http://dx.doi.org/10.1016/j.actatropica.2013.07.018>.
31. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS. 2004. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage *Plasmodium falciparum* infection in individuals in a malaria-endemic area of Africa. *J Immunol* 173:666–672. <http://dx.doi.org/10.4049/jimmunol.173.1.666>.
 32. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, Marsh K, Beeson JG. 2008. Variation in use of erythrocyte invasion pathways by *Plasmodium falciparum* mediates evasion of human inhibitory antibodies. *J Clin Invest* 118:342–351. <http://dx.doi.org/10.1172/JCI32138>.
 33. Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ, Muchiri EM, King CH, King CL, LaBeaud AD. 2015. Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. *PLoS Negl Trop Dis* 9:e0003466. <http://dx.doi.org/10.1371/journal.pntd.0003466>.
 34. Kalayjian BC, Malhotra I, Mungai P, Holding P, King CL. 2013. Marked decline in malaria prevalence among pregnant women and their offspring from 1996 to 2010 on the south Kenyan coast. *Am J Trop Med Hyg* 89:1129–1134. <http://dx.doi.org/10.4269/ajtmh.13-0250>.
 35. Malhotra I, Mungai P, Muchiri E, Ouma J, Sharma S, Kazura JW, King CL. 2005. Distinct Th1- and Th2-Type prenatal cytokine responses to *Plasmodium falciparum* erythrocyte invasion ligands. *Infect Immun* 73:3462–3470. <http://dx.doi.org/10.1128/IAI.73.6.3462-3470.2005>.
 36. Chatterjee S, Singh S, Sohoni R, Kattige V, Deshpande C, Chiplunkar S, Kumar N, Sharma S. 2000. Characterization of domains of the phosphoriboprotein P0 of *Plasmodium falciparum*. *Mol Biochem Parasitol* 107:143–154. [http://dx.doi.org/10.1016/S0166-6851\(99\)00226-1](http://dx.doi.org/10.1016/S0166-6851(99)00226-1).
 37. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA. 2004. Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. *J Clin Microbiol* 42:2403–2410. <http://dx.doi.org/10.1128/JCM.42.6.2403-2410.2004>.
 38. Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. 2005. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for *Plasmodium falciparum*. *Infect Immun* 73:2109–2115. <http://dx.doi.org/10.1128/IAI.73.4.2109-2115.2005>.
 39. Porter MD, Nicki J, Pool CD, DeBot M, Illam RM, Brando C, Bozick B, De La Vega P, Angra D, Spaccapelo R, Crisanti A, Murphy JR, Bennett JW, Schwenk RJ, Ockenhouse CF, Dutta S. 2013. Transgenic parasites stably expressing full-length *Plasmodium falciparum* circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. *Clin Vaccine Immunol* 20:803–810. <http://dx.doi.org/10.1128/CVI.00066-13>.
 40. Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. 2010. Immunization with preerythrocytic antigen CelTOS from *Plasmodium falciparum* elicits cross-species protection against heterologous challenge with *Plasmodium berghei*. *PLoS One* 5:e12294. <http://dx.doi.org/10.1371/journal.pone.0012294>.
 41. Sugiyama T, Suzue K, Okamoto M, Inselburg J, Tai K, Horii T. 1996. Production of recombinant SERA proteins of *Plasmodium falciparum* in *Escherichia coli* by using synthetic genes. *Vaccine* 14:1069–1076. [http://dx.doi.org/10.1016/0264-410X\(95\)00238-V](http://dx.doi.org/10.1016/0264-410X(95)00238-V).
 42. Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M. 2010. Evidences of protection against blood-stage infection of *Plasmodium falciparum* by the novel protein vaccine SE36. *Parasitol Int* 59:380–386. <http://dx.doi.org/10.1016/j.parint.2010.05.002>.
 43. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA. 2003. Development and pre-clinical analysis of a *Plasmodium falciparum* merozoite surface protein-1(42) malaria vaccine. *Mol Biochem Parasitol* 128:195–204. [http://dx.doi.org/10.1016/S0166-6851\(03\)00077-X](http://dx.doi.org/10.1016/S0166-6851(03)00077-X).
 44. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA. 2005. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of *Plasmodium falciparum* strain FVO expressed in *Escherichia coli* protects *Aotus nancymai* against challenge with homologous erythrocytic-stage parasites. *Infect Immun* 73:287–297. <http://dx.doi.org/10.1128/IAI.73.1.287-297.2005>.
 45. Angov E, Hillier CJ, Kincaid RL, Lyon JA. 2008. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. *PLoS One* 3:e2189. <http://dx.doi.org/10.1371/journal.pone.0002189>.
 46. Thompson JK, Triglia T, Reed MB, Cowman AF. 2001. A novel ligand from *Plasmodium falciparum* that binds to a sialic acid-containing receptor on the surface of human erythrocytes. *Mol Microbiol* 41:47–58. <http://dx.doi.org/10.1046/j.1365-2958.2001.02484.x>.
 47. Reed MB, Caruana SR, Batchelor AH, Thompson JK, Crabb BS, Cowman AF. 2000. Targeted disruption of an erythrocyte binding antigen in *Plasmodium falciparum* is associated with a switch toward a sialic acid-independent pathway of invasion. *Proc Natl Acad Sci U S A* 97:7509–7514. <http://dx.doi.org/10.1073/pnas.97.13.7509>.
 48. Gilberger TW, Thompson JK, Triglia T, Good RT, Duraisingh MT, Cowman AF. 2003. A novel erythrocyte binding antigen-175 paralogue from *Plasmodium falciparum* defines a new trypsin-resistant receptor on human erythrocytes. *J Biol Chem* 278:14480–14486. <http://dx.doi.org/10.1074/jbc.M211446200>.
 49. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, Lanar DE. 2002. Purification, characterization, and immunogenicity of the refolded ectodomain of the *Plasmodium falciparum* apical membrane antigen 1 expressed in *Escherichia coli*. *Infect Immun* 70:3101–3110. <http://dx.doi.org/10.1128/IAI.70.6.3101-3110.2002>.
 50. Dutta S, Haynes JD, Barbosa A, Ware LA, Snaveley JD, Moch JK, Thomas AW, Lanar DE. 2005. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of *Plasmodium falciparum*. *Infect Immun* 73:2116–2122. <http://dx.doi.org/10.1128/IAI.73.4.2116-2122.2005>.
 51. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: a systematic review and meta-analysis. *PLoS Med* 7:e1000218. <http://dx.doi.org/10.1371/journal.pmed.1000218>.
 52. Richards JS, Stanicic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of *Plasmodium falciparum* and protection from malaria and high-density parasitemia. *Clin Infect Dis* 51:e50–60. <http://dx.doi.org/10.1086/656413>.
 53. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. *Infect Immun* 69:3286–3294. <http://dx.doi.org/10.1128/IAI.69.5.3286-3294.2001>.
 54. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA. 2009. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting *Plasmodium falciparum* growth, as determined by the *in vitro* growth inhibition assay. *Clin Vaccine Immunol* 16:963–968. <http://dx.doi.org/10.1128/CVI.00042-09>.
 55. Dent AE, Moormann AM, Yohn CT, Kimmel RJ, Sumba PO, Vulule J, Long CA, Narum DL, Crabb BS, Kazura JW, Tisch DJ. 2012. Broadly reactive antibodies specific for *Plasmodium falciparum* MSP-1(19) are associated with the protection of naturally exposed children against infection. *Malar J* 11:287. <http://dx.doi.org/10.1186/1475-2875-11-287>.
 56. Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, Johnson AH. 2006. Multiplex assay for simultaneous measurement of antibodies to multiple *Plasmodium falciparum* antigens. *Clin Vaccine Immunol* 13:1307–1313. <http://dx.doi.org/10.1128/CVI.00183-06>.
 57. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, Moormann AM, Rochford R. 2009. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. *J Med Virol* 81:1088–1093. <http://dx.doi.org/10.1002/jmv.21485>.
 58. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW. 2009. Temporal stability of naturally acquired immunity to merozoite surface protein-1 in Kenyan adults. *Malar J* 8:162. <http://dx.doi.org/10.1186/1475-2875-8-162>.
 59. Staalsoe T, Giha HA, Dodoo D, Theander TG, Hviid L. 1999. Detection of antibodies to variant antigens on *Plasmodium falciparum*-infected erythrocytes by flow cytometry. *Cytometry* 35:329–336.

60. Beeson JG, Mann EJ, Elliott SR, Lema VM, Tadesse E, Molyneux ME, Brown GV, Rogerson SJ. 2004. Antibodies to variant surface antigens of *Plasmodium falciparum*-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. *J Infect Dis* 189:540–551. <http://dx.doi.org/10.1086/381186>.
61. Mackintosh CL, Christodoulou Z, Mwangi TW, Kortok M, Pinches R, Williams TN, Marsh K, Newbold CI. 2008. Acquisition of naturally occurring antibody responses to recombinant protein domains of *Plasmodium falciparum* erythrocyte membrane protein 1. *Malar J* 7:155. <http://dx.doi.org/10.1186/1475-2875-7-155>.
62. Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW, Moormann AM. 2007. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine *Plasmodium falciparum* MSP-119 haplotypes. *Am J Trop Med Hyg* 77:250–255.
63. Blackman MJ. 2000. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. *Curr Drug Targets* 1:59–83. <http://dx.doi.org/10.2174/1389450003349461>.
64. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S. 1992. A malaria merozoite surface protein (MSP1)-structure, processing and function. *Mem Inst Oswaldo Cruz* 87(Suppl 3):S37–S42.
65. Howell SA, Well I, Fleck SL, Kettleborough C, Collins CR, Blackman MJ. 2003. A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. *J Biol Chem* 278:23890–23898. <http://dx.doi.org/10.1074/jbc.M302160200>.
66. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. *Nat Med* 6:689–692. <http://dx.doi.org/10.1038/76272>.
67. Kaneko O, Kimura M, Kawamoto F, Ferreira MU, Tanabe K. 1997. *Plasmodium falciparum*: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. *Exp Parasitol* 86:45–57. <http://dx.doi.org/10.1006/expr.1997.4147>.
68. Kang Y, Long CA. 1995. Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of *Plasmodium falciparum*. *Mol Biochem Parasitol* 73:103–110. [http://dx.doi.org/10.1016/0166-6851\(95\)00102-7](http://dx.doi.org/10.1016/0166-6851(95)00102-7).
69. Lee EA, Flanagan KL, Odhiambo K, Reece WH, Potter C, Bailey R, Marsh K, Pinder M, Hill AV, Plebanski M. 2001. Identification of frequently recognized dimorphic T-cell epitopes in *Plasmodium falciparum* merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. *Am J Trop Med Hyg* 64:194–203.
70. Osier FH, Weedall GD, Verra F, Murungi L, Tetteh KK, Bull P, Faber BW, Remarque E, Thomas A, Marsh K, Conway DJ. 2010. Allelic diversity and naturally acquired allele-specific antibody responses to *Plasmodium falciparum* apical membrane antigen 1 in Kenya. *Infect Immun* 78:4625–4633. <http://dx.doi.org/10.1128/IAI.00576-10>.
71. Amaratunga C, Lopera-Mesa TM, Brittain NJ, Cholera R, Arie T, Fujioka H, Keefer JR, Fairhurst RM. 2011. A role for fetal hemoglobin and maternal immune IgG in infant resistance to *Plasmodium falciparum* malaria. *PLoS One* 6:e14798. <http://dx.doi.org/10.1371/journal.pone.0014798>.
72. D'Alessandro U, Ubben D, Hamed K, Ceesay SJ, Okebe J, Taal M, Lama EK, Keita M, Koivogui L, Nahum A, Bojang K, Sonko AA, Lalya HF, Brabin B. 2012. Malaria in infants aged less than 6 months: is it an area of unmet medical need? *Malar J* 11:400. <http://dx.doi.org/10.1186/1475-2875-11-400>.
73. Kassim OO, Ako-Anai KA, Torimiro SE, Hollowell GP, Okoye VC, Martin SK. 2000. Inhibitory factors in breastmilk, maternal and infant sera against *in vitro* growth of *Plasmodium falciparum* malaria parasite. *J Trop Pediatr* 46:92–96. <http://dx.doi.org/10.1093/tropej/46.2.92>.
74. Jaspan HB, Lawn SD, Safrin JT, Bekker LG. 2006. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. *AIDS* 20:483–494. <http://dx.doi.org/10.1097/01.aids.0000210602.40267.60>.
75. Duah NO, Miles DJ, Whittle HC, Conway DJ. 2010. Acquisition of antibody isotypes against *Plasmodium falciparum* blood stage antigens in a birth cohort. *Parasite Immunol* 32:125–134. <http://dx.doi.org/10.1111/j.1365-3024.2009.01165.x>.
76. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, Ghani AC. 2014. Dynamics of the antibody response to *Plasmodium falciparum* infection in African children. *J Infect Dis* 210:1115–1122. <http://dx.doi.org/10.1093/infdis/jiu219>.
77. Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW, Blackman MJ. 2007. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. *J Biol Chem* 282:7431–7441.
78. Feng ZP, Keizer DW, Stevenson RA, Yao S, Babon JJ, Murphy VJ, Anders RF, Norton RS. 2005. Structure and inter-domain interactions of domain II from the blood-stage malarial protein, apical membrane antigen 1. *J Mol Biol* 350:641–656. <http://dx.doi.org/10.1016/j.jmb.2005.05.011>.
79. Mutapi F, Roussilhon C, Mduluzza T, Druilhe P. 2007. Anti-malaria humoral responses in children exposed to *Plasmodium falciparum* and *Schistosoma haematobium*. *Mem Inst Oswaldo Cruz* 102:405–409. <http://dx.doi.org/10.1590/S0074-02762007005000046>.
80. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Perignon JL, Druilhe P. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. *PLoS Med* 4:e320. <http://dx.doi.org/10.1371/journal.pmed.0040320>.
81. Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM, Lemnge MM, Gowda CD, Todd JE, Corran PH, Riley EM. 2006. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. *Infect Immun* 74:257–264. <http://dx.doi.org/10.1128/IAI.74.1.257-264.2006>.
82. Hviid L, Staaloe T. 2004. Malaria immunity in infants: a special case of a general phenomenon? *Trends Parasitol* 20:66–72. <http://dx.doi.org/10.1016/j.pt.2003.11.009>.
83. Marsh K, Howard RJ. 1986. Antigens induced on erythrocytes by *P. falciparum*: expression of diverse and conserved determinants. *Science* 231:150–153. <http://dx.doi.org/10.1126/science.2417315>.
84. Reeder JC, Rogerson SJ, al-Yaman F, Anders RF, Coppel RL, Novakovic S, Alpers MP, Brown GV. 1994. Diversity of agglutinating phenotype, cytoadherence, and rosette-forming characteristics of *Plasmodium falciparum* isolates from Papua New Guinean children. *Am J Trop Med Hyg* 51:45–55.
85. Kinyanjui SM, Bull P, Newbold CI, Marsh K. 2003. Kinetics of antibody responses to *Plasmodium falciparum*-infected erythrocyte variant surface antigens. *J Infect Dis* 187:667–674. <http://dx.doi.org/10.1086/373994>.
86. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. *J Exp Med* 172:379–382. <http://dx.doi.org/10.1084/jem.172.1.379>.
87. Tham WH, Healer J, Cowman AF. 2012. Erythrocyte and reticulocyte binding-like proteins of *Plasmodium falciparum*. *Trends Parasitol* 28:23–30. <http://dx.doi.org/10.1016/j.pt.2011.10.002>.
88. Dent A, Malhotra I, Mungai P, Muchiri E, Crabb BS, Kazura JW, King CL. 2006. Prenatal malaria immune experience affects acquisition of *Plasmodium falciparum* merozoite surface protein-1 invasion inhibitory antibodies during infancy. *J Immunol* 177:7139–7145. <http://dx.doi.org/10.4049/jimmunol.177.10.7139>.
89. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspling-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG. 2015. Human antibodies fix complement to inhibit *Plasmodium falciparum* invasion of erythrocytes and are associated with protection against malaria. *Immunity* 42:580–590. <http://dx.doi.org/10.1016/j.immuni.2015.02.012>.
90. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG. 2014. Opsonic phagocytosis of *Plasmodium falciparum* merozoites: mechanism in human immunity and a correlate of protection against malaria. *BMC Med* 12:108. <http://dx.doi.org/10.1186/1741-7015-12-108>.
91. Ambroggio X, Jiang L, Aebig J, Obiakor H, Lukszo J, Narum DL. 2013. The epitope of monoclonal antibodies blocking erythrocyte invasion by *Plasmodium falciparum* map to the dimerization and receptor glycan binding sites of EBA-175. *PLoS One* 8:e56326. <http://dx.doi.org/10.1371/journal.pone.0056326>.
92. Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, Long CA, Narum DL, Miller LH. 2014. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. *Proc Natl Acad Sci U S A* 111:10311–10316. <http://dx.doi.org/10.1073/pnas.1409928111>.